Introduction

A decade ago, the description of a primitive novel cell type capable of differentiating into cells expressing a mature endothelial cell phenotype and their capacity to incorporate into regions of active angiogenesis, witnessed the emergence of endothelial progenitor cell (EPC) biology
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. The development and maturation of this new concept in vascular biology has resulted in numerous studies describing the role of EPCs in a myriad of disease states where abnormalities of the vasculature have been implicated. Thus, from pre-eclampsia to pulmonary hypertension, erythropoietin administration to erectile dysfunction and cancer to coronary disease the discovery of EPCs has added greatly to the understanding of basic pathophysiology. However, it is in the study of coronary artery disease where this paradigm shift has had greatest impact, not only regarding basic disease mechanisms, but in the rapid translation of these findings into a clinical context. The purpose of this review is to outline the current understanding of the EPC phenotypes and their relationship with risk factors for coronary disease. In addition, the potential problems of EPC dysfunction and its impact on percutaneous intervention will be appraised together with both pharmacological and stent based strategies to augment EPC number and function.
Defining the endothelial progenitor cell
Flow cytometry
EPCs have some basic characteristics of mature endothelial cells, including expression of markers such as CD34, a haematopoietic stem/progenitor cell marker and VEGFR2, one of the receptors for vascular endothelial growth factor (also known as Flk-1 and KDR). Early studies also described additional EPC characteristics such as incorporation of acetylated LDL and binding of lectins. Human haematopoietic stem cells and early EPCs also express another stem/progenitor cell marker which is not expressed by more differentiated cells and is therefore used to distinguish
Colony forming assays
In the context of these measurement difficulties, and also the requirement to assess not only EPC number but also function, the use of colony forming unit assays (CFU-EPC) has also been widely described 1, [3] [4] [5] . to the repair mechanism 17 ( Figure 2 28 . Chronic renal impairment exerts a similarly deleterious influence on EPC functionality 29, 30 . Interestingly, essential hypertension by itself appears to bear no correlation with EPC number and functional activity 31 . EPC activity has also recently been speculated to contribute as a surrogate risk factor to explain the gender differences in vascular disease predisposition, with both proliferative and migratory capacity being significantly greater in women 32 . 47 . 19, 49, 50 . 
Late stent thrombosis and delayed re-endothelialisation
Clinical applications and ongoing trials
Shifting of the vascular repair paradigm away from localised cytotoxic/cytostatic drug elution platforms to accelerated stent endothelialisation is an attractive concept. Regeneration of damaged endothelium is the fundamental process in vascular repair. Attempts to augment this process should reduce cardiovascular events associated with thrombosis, restenosis and hypertension
Initial attempts to seed mature EC, using various delivery devices were frustrated by the rapid loss of seeded cells and in particular, the detachment of adhered cells to the vessel wall once antegrade coronary flow was resumed
. Attention has turned to the therapeutic value of EPCs and transplantation of EPCs for seeding of prosthetic grafts, stents or engineered blood vessels to create a bio-active EC layer has been successfully demonstrated
